GlassScriptPhysician profile
John A Mcgreal
NPI 1689661886
$126,350.11
in general payments reported to CMS, 2019-2025
24 companies · $25K in 2025
The $25K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,329 · 2020: $517 · 2021: $21K · 2022: $17K · 2023: $28K · 2024: $31K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $82K · Food and Beverage: $2,716.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $81,602.45 |
| Food and Beverage | $2,715.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abb Con-Cise Optical Group LLC | $118,027.45 | 2021-2025 | Contact Lens |
| Shire North American Group INC | $2,839.69 | 2019 | |
| Alimera Sciences, INC. | $814.57 | 2019-2024 | Iluvien, Yutiq |
| Kala Pharmaceuticals, INC. | $803.69 | 2021-2022 | |
| Abbvie INC. | $655.76 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $557.96 | 2022-2024 | Miebo, Vyzulta, Infuse |
| Astellas Pharma US INC | $498.91 | 2023-2025 | Izervay |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $339.31 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $296.34 | 2024-2025 | Acthar |
| Apellis Pharmaceuticals, INC. | $279.14 | 2024-2025 | Syfovre |
| Eyevance Pharmaceuticals LLC | $199.99 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $157.76 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $145.63 | 2019-2023 | Eylea |
| Amgen INC. | $124.69 | 2024 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $121.17 | 2025 | Xdemvy |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $89.82 | 2024-2025 | Vabysmo |
| Allergan, INC. | $80.18 | 2019 | |
| Sight Sciences, INC. | $77.73 | 2019 | |
| Biogen, INC. | $54.65 | 2023-2024 | Byooviz |
| Harrow Eye, LLC | $47.67 | 2023-2025 | Iheezo |
| Alcon Vision LLC | $41.35 | 2022-2023 | Simbrinza |
| Eyepoint US, INC. | $38.68 | 2022-2023 | |
| Glaukos Corporation | $31.97 | 2023 | |
| Ani Pharmaceuticals, INC. | $26.00 | 2025 | Iluvien |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mcgreal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.